These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24204660)

  • 1. Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.
    Lu J; Zang J; Li H
    PLoS One; 2013; 8(10):e76713. PubMed ID: 24204660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis.
    Du Q; Wu B; Wang YJ; Yang S; Zhao YY; Liang YY
    Curr Med Res Opin; 2013 Nov; 29(11):1487-94. PubMed ID: 23927568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Piccinni MN; D'Angelo A; Fogari E; Maffioli P
    Diabet Med; 2013 Jul; 30(7):846-54. PubMed ID: 23413771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Piccinni MN; D'Angelo A; Fogari E; Maffioli P
    Diabetes Technol Ther; 2013 Mar; 15(3):214-22. PubMed ID: 23427864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.
    Yoon KH; Shockey GR; Teng R; Golm GT; Thakkar PR; Meehan AG; Williams-Herman DE; Kaufman KD; Amatruda JM; Steinberg H
    Int J Clin Pract; 2011 Feb; 65(2):154-64. PubMed ID: 21235696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
    Derosa G; Carbone A; Franzetti I; Querci F; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
    Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
    Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sitagliptin on markers of beta-cell function: a meta-analysis.
    Riche DM; East HE; Riche KD
    Am J Med Sci; 2009 May; 337(5):321-8. PubMed ID: 19322069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
    Takihata M; Nakamura A; Tajima K; Inazumi T; Komatsu Y; Tamura H; Yamazaki S; Kondo Y; Yamada M; Kimura M; Terauchi Y
    Diabetes Obes Metab; 2013 May; 15(5):455-62. PubMed ID: 23279373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.
    Lim S; An JH; Shin H; Khang AR; Lee Y; Ahn HY; Yoon JW; Kang SM; Choi SH; Cho YM; Park KS; Jang HC
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):215-23. PubMed ID: 21955147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
    J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.
    Chapell R; Gould AL; Alexander CM
    Diabetes Obes Metab; 2009 Nov; 11(11):1009-16. PubMed ID: 19614948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
    Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
    Asai S; Ohta A; Kato H; Sada Y; Nagai Y; Kondo A; Sasaoka T; Tanaka Y
    Endocr J; 2014; 61(12):1213-20. PubMed ID: 25231694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.